This is a different matter. It would be worth 4B+ if it becomes a standard of care. The PPS is low because the major players for whatever reasons apparently give it a very low probability of becoming a SOC at this point. PPHM management and PR is partially to blame for it and for low share price.
I would appreciate more discussion on the scientific/clinical side of Peregrine. It is in that realm that ultimate success or failure resides. When the discussion here is sidetracked by debates with those who clearly expect/wish/expect-to-profit-from Peregrine's failure, the real issues are obscured IMO.